

Epsilon Healthcare Limited
ACN: 614 508 039

Appendix 4D and Consolidated
Interim Financial Report for the
Half Year Ended
30 June 2025

APPENDIX 4D

1.	Name of Entity	Epsilon Healthcare Limited		
		ACN 614 508 039		
	Half year ended	30 June 2025		
	Reporting period	1 January 2025 to 30 June 2025		
	Previous period	1 January 2024 to 30 June 2024		
2.	Results for announcement to the market			
		30 June 25	30 June 24	% Change Up (Down)
2.1	Revenues from continuing operations	3,401,788	2,869,288	19%
2.2	Loss from continuing operations after tax attributable to members	(2,068,860)	(1,438,889)	(44%)
2.3	Net loss attributable to members	(2,068,860)	(1,438,889)	(44%)
2.4	Proposed dividends	Nil	Nil	
2.5	Record date for dividend entitlement	N/A	N/A	

2.6 Brief explanation of figures in 2.1 to 2.5 necessary to enable the figures to be understood

The Company's business units saw an increase of 19% in revenue to \$3,401,788 as a result of work undertaken to build new client engagements and to rebuild and consolidate existing client relationships. The introduction and commencement of operations of the new business segment, Epsilon Pharmacy is recording better than expected revenues.

Net loss amounted to \$2,068,860, compared to \$1,438,889 in the comparative period. This increase was attributable to administrator's fees and interest and loan charges associated with financing activities. There were also \$561,000 in fees incurred for remediation work being undertaken by Ure Lynam & Co reflecting the high cost of administrative and accounting services that were a direct result of the voluntary administration.

	30 June 2025 Cents	31 December 2024 Cents	% Change Up (Down)
3. Net tangible assets per security	(2.49)	(0.60)	(315%)
*Sale of land and buildings in June 2025 main driver of decrease in NTA per security for the period.			
4. During the period, the Group did not gain or cease control of any subsidiaries.			
5. There were no payments of dividends during the reporting period.			
6. There is no dividend reinvestment plan in operation.			
7. There are no associates or joint venture entities.			
8. The Company is not a foreign entity.			
9. This report is based on financial statements that have been reviewed. The review report is included in the 30 June 2025 Half Year Report.			

The Company's half year report follows.

Yours faithfully,



Alan Beasley
Chairman
16 December 2025

ACN: 614 508 039

**Consolidated Interim Financial
Report for the Half Year Ended
30 June 2025**

For personal use only

Epsilon Healthcare Limited
Consolidated Interim Financial Report
30 June 2025

Table of Contents

	Page
Corporate Directory	1
Directors' Report	2
Auditor's Independence Declaration	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Changes in Equity	8
Consolidated Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	19
Independent Auditor's Review Report	20

Corporate Directory

Directors

Alan Beasley - Chairman

Peter Giannopoulos - Executive Director

Zoe Hutchings - Non-Executive Director

Company Secretary

Daniel Kaplon (Appointed 27 August 2025)

Registered Office & Principal Place of Business

5 Goodyear Street

Southport QLD 4215

Website

epsilonhealthcare.com.au

Auditor

RSM Australia Partners

Level 27, 120 Collins Street

Melbourne VIC 3000, Australia

Directors' Report

The directors present this report, together with the financial statements, on the consolidated entity (referred to hereafter as "EPN" or the 'Group') consisting of Epsilon Healthcare Limited (referred to hereafter as the 'Company') and the entities it controlled at the end of, or during, the half-year ended 30 June 2025.

Directors

The following persons were directors of the Company during the financial period and up to the date of this report, unless otherwise indicated:

Alan Beasley	Chairman
Peter Giannopoulos	Executive Director
Zoe Hutchings	Non-Executive Director

Review of Operations and Financial Results

The net loss after income tax for the half-year ended 30 June 2025 was \$2,068,860 (30 June 2024 loss: \$1,438,889).

Principal Activities and Strategy

Epsilon Healthcare is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. Epsilon Healthcare offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care.

Review of Operations

For the 6 months ended 30 June 2025:

Although revenues were affected by reduced client confidence during the administration period, the 6-month period to June 2025 delivered a strong rebound. Operational activity accelerated, revenue increased by 19% compared to the prior corresponding period, and the Group successfully completed several major corporate restructurings. In addition, new strategic initiatives were launched, positioning the business for sustained value creation and positive momentum heading into the next half year.

Significant Changes in State of Affairs

Corporate Structure

The Group achieved substantial progress in restoring stability and clarity to its corporate structure. The Deed of Company Arrangement ("DOCA") for Epsilon Clinics Pty Limited was effectuated on 19 February 2025, followed by Epsilon Pharma Pty Limited on 2 April 2025, and culminating with Epsilon Healthcare Limited on 26 June 2025. These milestones mark an important step forward, strengthening the Group's foundation and supporting a renewed confidence in its future direction.

Capital raisings and funding arrangements

EPN successfully advanced its capital initiatives, issuing \$555,000 of loan notes that were converted to 27,750,000 shares on 30 June 2025. This conversion enhances the Company's capital position and supports continued investment in diversification and growth opportunities over the near term.

During the period, the Company successfully completed a strategic sale and leaseback transaction of its manufacturing property. The \$6.7 million sale and long-term leaseback allows for continued use and occupancy of the site, ensuring the exclusive occupation of the site, operational continuity and security of tenure for its manufacturing facility activities. The sale proceeds were used to substantially improve the company's debt to equity ratio and financial exposure by extinguishing in full the \$4.8m secured loan facility, repayment of other short-term debts & providing working capital to support some of the strategic and operational objectives of the organisation.

ASX suspension

The Company's securities remain suspended from quotation on the ASX pending compliance with ASX requirements. The Board is undertaking remedial actions to address matters raised by the ASX, with a view to seeking reinstatement when appropriate.

Events Occurring After the Balance Date

On 5 November 2025, the Managing Director has personally made a facility available to the consolidated entity of \$1 million to assist the consolidated entity in meeting its obligations as and when they fall due for a period of at least 12 months.

On 5 December 2025, the consolidated entity secured an extension to 24 March 2027 on the repayment of its syndicate loan borrowings as disclosed in Note 5 *Borrowings*. As at 31 October 2025, the amount of these borrowings has reduced to \$2,332,939.

On 5 December 2025, a letter of support was received from the directors to defer settlement of \$808,000 in liabilities payable to the Directors until such time that the consolidated entity can make these payments without impacting its solvency.

Apart from the above, there were no other matters, or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect:

- a. The Group's operations in future financial years; or
- b. The results of those operations in future financial years; or
- c. The Group's state of affairs in future financial years

Likely Developments and Expected Results of Operations

Information on likely developments in the operations of the Group and the expected results of operations have not been included in these financial statements because the directors believe it could potentially result in unreasonable prejudice to the Group.

Dividends

No dividends were proposed or paid to members during the financial period (2024: \$Nil).

Proceedings on Behalf of the Group

Epsilon Healthcare Limited ("EPN") filed proceedings on 21 May 2025 in the NSW Supreme Court against the former director and chairman Josh (Xiao) Cui and Watercrest Capital Pty Limited, a company for which Josh (Xiao) Cui is the sole director and secretary. The proceedings relate to agreements purportedly entered by EPN and payments made by EPN to Watercrest Capital Pty Limited and other parties.

Auditor's Independence Declaration

The auditor's independence declaration under section 307C of the *Corporations Act 2001* is set out on page 6.

Signed in accordance with a resolution of the Board of Directors.

On behalf of the Directors:

A handwritten signature in dark ink, appearing to read 'A Beasley', with a stylized flourish at the end.

Alan Beasley

Chairman

16 December 2025

RSM Australia Partners

Level 27, 120 Collins Street Melbourne VIC 3000

PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000

F +61 (0) 3 9286 8199

www.rsm.com.au

AUDITOR'S INDEPENDENCE DECLARATION

As lead auditor for the review of the financial report of Epsilon Healthcare Limited and its controlled entities for the half-year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.



RSM AUSTRALIA PARTNERS



B Y CHAN
Partner

Dated: 16/12/2025
Melbourne, Victoria

Epsilon Healthcare Limited
Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the Half-year Ended 30 June 2025

	Notes	30 June 2025 \$	30 June 2024 \$
Revenue from continuing operations		3,401,788	2,869,288
Other income		29,306	-
Cost of inventory consumed		(1,785,793)	(487,855)
Freight and other selling expenses		(182,241)	(146,415)
Professional expenses		(848,683)	(141,771)
Corporate and consulting expenses		(641,003)	(1,060,934)
Plant and facility costs		(34,762)	(212,088)
Licence and registration fees		(65,291)	(43,223)
Employee benefits expense		(1,454,176)	(1,134,530)
Advertising and promotion expenses		(24,231)	-
Insurance expenses		(243,568)	(294,699)
Bad debts recovered/(expense)		(931)	-
Depreciation and amortisation expense		(54,575)	(726,536)
Interest expenses		(701,603)	(385,187)
Office and occupancy expenses		(51,672)	(5,608)
Administration expenses		(180,805)	(73,854)
Foreign exchange (loss)/gain		(5,862)	(3,062)
Facilitation and establishment cost		(191,556)	(25,455)
Loss before income tax		(3,035,659)	(1,871,927)
Income tax benefit/(expense)		966,799	433,038
Loss for the year		(2,068,860)	(1,438,889)
Other comprehensive income		-	-
Total comprehensive loss for the year		(2,068,860)	(1,438,889)
Earnings per share			
- Basic/diluted losses per share		(0.60)	(0.48)
(Cents)			

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

Epsilon Healthcare Limited
Consolidated Statement of Financial Position
As at 30 June 2025

		30 June 2025	31 December 2024 (Restated)
	Notes	\$	\$
Assets			
Current Asset			
Cash and cash equivalents		923,667	1,565,647
Trade and other receivables		1,463,482	1,091,931
Inventory		449,939	528,991
Assets held for sale	11	-	6,700,000
Other current assets		477,726	502,736
Total Current Assets		3,314,814	10,389,305
Non-Current Assets			
Right-of-use-assets		5,649,288	-
Other non-current assets		326,000	66,000
Total Non-Current Assets		5,975,288	66,000
Total Assets		9,290,102	10,455,305
Liabilities			
Current Liabilities			
Trade and other payables		2,419,224	2,590,691
Contract liabilities		692,169	230,891
Borrowings	5	3,398,537	7,850,755
Employee benefits		650,668	795,994
Lease liabilities		427,954	33,861
Total Current Liabilities		7,588,552	11,502,192
Non-Current Liabilities			
Deferred tax liability		-	966,799
Employee benefits		90,294	63,529
Lease liabilities		5,232,231	-
Total Non-Current Liabilities		5,322,525	1,030,328
Total Liabilities		12,911,077	12,532,520
Net Assets		(3,620,975)	(2,077,215)
Equity			
Contributed equity	7	48,058,585	47,533,485
Reserves	8	50,000	3,980,197
Accumulated losses		(51,729,560)	(53,590,897)
Total Equity		(3,620,975)	(2,077,215)

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

Epsilon Healthcare Limited
Consolidated Statement of Changes in Equity
For the Half-year Ended 30 June 2025

	Contributed equity	Accumulated losses	Reserves	Total
	\$	\$	\$	\$
At 1 January 2024	46,813,485	(48,097,161)	8,822,899	7,539,223
Loss for the year	-	(1,438,889)	-	(1,438,889)
Other comprehensive income	-	-	-	-
Total comprehensive loss	-	(1,438,889)	-	(1,438,889)
Total transactions with owners	-	-	-	-
At 30 June 2024	46,813,485	(49,536,050)	8,822,899	6,100,334
At 1 January 2025	47,533,485	(53,590,897)	3,980,197	(2,077,215)
Loss for the year	-	(2,068,860)	-	(2,068,860)
Other comprehensive income	-	-	-	-
Total comprehensive loss	-	(2,068,860)	-	(2,068,860)
Issue of share capital	525,100	-	-	525,100
Options vesting expense and expiration	-	63,000	(63,000)	-
Revaluation reserve – transfer to accumulated losses	-	3,867,197	(3,867,197)	-
Total transactions with owners	525,100	3,930,197	(3,930,197)	525,100
At 30 June 2025	48,058,585	(51,729,560)	50,000	(3,620,975)

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

Epsilon Healthcare Limited
Consolidated Statement of Cash Flows
For the Half-year Ended 30 June 2025

	30 June 2025	30 June 2024
	\$	\$
Cash flows from operating activities		
Receipts from customers	3,490,581	2,606,248
Payments to suppliers and employees	(5,595,368)	(3,054,510)
Finance costs	(736,755)	(1,001,649)
Net cash outflow from operating activities	(2,841,542)	(1,449,911)
Cash flows from investing activities		
Proceeds from disposal of property, plant and equipment	6,700,000	-
Payment of lease security deposit	(244,000)	-
Net cash inflow from investing activities	6,456,000	-
Cash flows from financing activities		
Principal payment of lease liabilities	(77,539)	-
Principal payment of borrowings	(4,864,000)	(3,149,782)
Proceeds from borrowings	160,000	7,580,485
Proceeds from shares issued (net of costs)	525,100	-
Net cash inflow/(outflow) from financing activities	(4,256,439)	4,430,703
Net (decrease)/increase in cash and cash equivalents	(641,981)	2,980,792
Cash and cash equivalents at the beginning of the period	1,565,647	343,013
Cash and cash equivalents at end of the period	923,667	3,323,805

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

Epsilon Healthcare Limited
Notes to the Financial Statements
For the Half-Year ended 30 June 2025

Material Accounting Policies

1. Basis of preparation of half year report

The general-purpose financial statements for the interim half-year reporting period ended 30 June 2025 has been prepared in accordance with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

The interim report does not include all the notes normally included in annual consolidated financial report. Accordingly, this report should be read in conjunction with the annual consolidated financial report for the year ended 31 December 2024 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirement of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

2. Going Concern

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

As disclosed in the financial statements, the consolidated entity incurred a loss of \$2,068,860 and had net cash outflows from operating activities of \$2,841,542 for the half-year ended 30 June 2025. As at that date the consolidated entity had net current liabilities of \$4,273,737 and net liabilities of \$3,620,975.

The Directors believe that it is reasonably foreseeable that consolidated entity will continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report after consideration of the following factors:

As disclosed in Note 10 *Events occurring after the balance date*:

- On 5 November 2025, the Managing Director has personally made a facility available to the consolidated entity of \$1 million to assist the consolidated entity in meeting its obligations as and when they fall due for a period of at least 12 months.
- On 5 December 2025, the consolidated entity secured an extension to 24 March 2027 on the repayment of its syndicate loan borrowings, as disclosed in Note 5 *Borrowings*. The value of the secured loan including interest as at 31 October 2025 is \$2,332,939.
- The consolidated entity has included in trade and other payables and employee benefits – current, a total of \$808,000 payable to its directors in relation to unpaid director's fees, wages and short-term incentives. On 5 December 2025, a letter of support was received from the directors to defer settlement of these liabilities until such time that the consolidated entity can make these payments without impact to its solvency.

The consolidated entity has lodged on the ASX its Appendix 4C quarterly cash flow report (unaudited) for the 3-months ending 30 September 2025 which showed positive cash inflows from operating activities of \$627,000.

The directors have prepared the consolidated entity's cash flow forecasts for the next 12 months from the date of this report and conclude this forecast, being a best estimate of the consolidated entity's performance for this forecasted period, supports that the consolidated entity will have a positive cash balance during this period, will be able to pay all of its operational and financial commitments for the 12 months, and that the consolidated entity will continue as a going concern.

4. Interests in Subsidiaries

Name of subsidiary	Country of Incorporation	Ownership interest	Ownership interest
		30 June 2025	30 June 2024
Canndeo Pty Ltd	Australia	100%	100%
Epsilon Pharma Pty Ltd	Australia	100%	100%
Metra Holdings Pty Ltd	Australia	100%	100%
Epsilon Clinics Pty Ltd	Australia	100%	100%
Epsilon Biotech Pty Ltd	Australia	100%	100%
Canna Clinics Pty Ltd	Australia	100%	100%
Green Horizon Australia Pacific Pty Ltd	Australia	100%	100%

5. Borrowings

During the 6-month period to 30 June 2025, the Company has been able to obtain the following additional financing facilities:

- The repayment terms of the secured loan facility entered on 24 June 2024 has been extended to 24 March 2027 with the amount outstanding as of 30 June 2025 at \$3,108,019 with total borrowings of \$3,398,537. Since balance date \$916,934 has been repaid since balance date. The value of the secured loan including interest as at 31 October 2025 is \$2,332,939.

The insurance funding loans are loan facilities to finance the cost of the Group's insurance premiums. These funding loans are secured over any remaining outstanding insurance premiums and are repayable in monthly equal instalments.

6. Operating Segments

Identification of Reportable Segments

The Group has three reportable operating segments, which reflect the internal management structure and the information reported to the Chief Operating Decision Maker ("CODM"), identified as the Board of Directors. Operating segments are identified based on the nature of the products and services provided.

The reportable segments are:

1. Contract Development and Manufacturing ("CDMO") – manufacture of active pharmaceutical ingredients (API) and finished formulations for domestic and international customers.
2. Telehealth Medical Practice – provision of telehealth medical consultation services.
3. Pharmacy Services – dispensing and pharmacy-related fulfilment services.

All remaining corporate and administration activities are presented as Unallocated.

Basis of Preparation

Segment information is prepared in accordance with the internal management reports reviewed by the CODM. The accounting policies adopted for segment reporting are consistent with those used in the preparation of the consolidated financial statements.

Segment revenue represents revenue directly attributable to each segment. Inter-segment revenues, if any, are recorded at arm's-length and eliminated on consolidation. Segment results are measured on a net profit after tax basis, consistent with the consolidated statement of profit or loss. The CODM also reviews segment assets and liabilities. Assets and liabilities are allocated to segments based on the operations of the segment and the location of the assets.

The revenues and profit generated by each of the Group's operating segments and segment assets and liabilities are summarised as follows:

Half-year to 30 June 2025	Contract Development and Manufacturing	Telehealth Medical Practice	Pharmacy	Unallocated	Total
	\$	\$	\$	\$	\$
Revenue					
External Sales	2,865,686	-	278,713	-	3,144,400
External Services	-	257,389	-	-	257,389
Total segment revenue	2,865,686	257,389	278,713	-	3,401,788
EBITDA	(630,737)	(81,781)	(101,146)	(1,486,143)	(2,299,807)
Depreciation and amortisation	54,575	-	-	-	54,575
Segment (Loss)/profit before income tax expense	(2,561,805)	(83,032)	(101,146)	(289,675)	(3,035,658)
Segment (Loss)/profit after income tax expense	(1,595,007)	(83,032)	(101,146)	(289,675)	(2,068,860)
Segment Assets	12,026,986	552,598	393,676	(3,683,158)	9,290,102
Segment Liabilities	27,949,332	843,608	494,723	(16,376,586)	12,911,077
Half-year to 30 June 2024	Contract Development and Manufacturing	Telehealth Medical Practice	Pharmacy	Unallocated	Total
	\$	\$	\$	\$	\$
Revenue					
External Sales	2,478,795	-	-	-	2,478,795
External Services	-	390,493	-	-	390,493
Total segment revenue	2,478,795	390,493	-	-	2,869,288
EBITDA	(15,418)	(26,395)	-	(730,684)	(772,497)
Depreciation and amortisation	677,640	67	-	48,832	726,536
Segment (Loss)/profit before income tax expense	(2,199,424)	(26,462)	-	353,959	(1,871,927)
Segment (Loss)/profit after income tax expense	(1,766,386)	(26,462)	-	353,959	(1,438,889)
Segment Assets	17,913,057	897,295	-	(1,553,810)	17,256,542
Segment Liabilities	23,750,999	967,076	-	(13,561,867)	11,156,208

*Reconciliations of Segment Information to Consolidated Results
For the Half-Year Ended 30 June 2025*

Reconciliation item	30 June 2025	30 June 2024
	\$	\$
Segment profit/(loss) after tax	(1,779,185)	(1,792,849)

Unallocated profit/(loss)	(289,675)	353,960
Consolidated loss after tax	(2,068,860)	(1,438,889)
Segment assets	12,973,260	18,810,352
Unallocated assets	(3,683,158)	(1,553,810)
Total assets	9,290,102	17,256,542
Segment liabilities	29,287,663	24,718,075
Unallocated liabilities	(16,376,586)	(13,561,867)
Total liabilities	12,911,077	11,156,208

Geographical Information

The Group operates wholly within Australia. Accordingly, no geographical disclosures are presented

7. Contributed Equity

Shares issued are summarised as follows:

	As at 30 June 2025		As at 31 December 2024	
	No. of shares	\$	No. of shares	\$
At the beginning of the period	345,354,011	47,533,485	300,354,011	46,813,485
Share placement (net)	-	100	38,750,000	620,000
Issue of ordinary shares as consideration of repayment of loan borrowing	26,250,000	525,000	6,250,000	100,000
Balance at end of the period	371,604,011	48,058,585	345,354,011	47,533,485

8. Reserves

	As at 30 June 2025	As at 31 December 2024
Options reserve (a)	50,000	113,000
Asset revaluation reserve (b)	-	3,867,197
Balance at end of the period	50,000	3,980,197

(a) Options reserve	As at 30 June 2025		As at 31 December 2024	
	No. of shares	\$	No. of shares	\$
At the beginning of the period	35,000,000	113,000	30,000,000	63,000
Options issued to KMPs	-	-	5,000,000	50,000
Options lapsed	(30,000,000)	(63,000)	-	-
Balance at end of the period	5,000,000	50,000	35,000,000	113,000

(b) Asset revaluation reserve

	As at 30 June 2025	As at 31 December 2024
At the beginning of the period	3,867,197	8,709,899
Movement in the financial period	(3,867,197)	(4,842,702)
Balance at end of the period	-	3,867,197

9. Related Party Transactions

(a) Transactions with related parties

	As at/Period Ended 30 June 2025	As at/Period Ended 30 June 2024
Services received		
Consulting services provided by SV Partners (NSW) Pty Ltd, acting as the company's administrators	310,916	933,748
Accounting services provided by KS Black & Co, a related party of Mr Stuart Cameron.	-	5,580
Total services received	310,916	939,328
Interest paid/payable		
Interest paid on a secured loan balance provided by Australia Oracles Holding Pty Limited, a related party of an associate of Mr Josh Cui.	-	402,144
Interest paid/payable on a secured loan balance provided by Lekarna, a related party of Mr Peter Giannopoulos.	91,088	-
Total interest paid	91,088	402,144
Liabilities		
Current liabilities		
Unsecured loan balance provided by Alpha Securities Pty Limited, a related party of an associate of Mr Josh Cui.	-	60,000
Secured loan balance provided by investor funding of whom Mr Alan Beasley and Mr Peter Giannopoulos were loan contributors. who are also related parties. The portion of the loan balances from Mr Alan Beasley and Mr Peter Giannopoulos (both related parties).	834,630	-
Unsecured loan balance provided by Peter Giannopoulos	160,000	-
Total loans payable	994,630	60,000

The Group has financial liabilities with related parties, comprising unsecured and secured loan balances disclosed above under current liabilities. These financial liabilities are recognised at amortised cost in accordance with AASB 9 *Financial Instruments*.

Management has assessed the fair value of the related party loan balances by reference to prevailing market interest rates for similar instruments with comparable credit risk, tenor, security profile and subordination. The Directors consider that the carrying value of the related party loans at reporting date approximates their fair value, primarily due to the short-term nature

of the facilities, the absence of significant transaction costs, and the fact that interest rates are broadly reflective of market conditions applicable to the Group at the time the facilities were entered into.

Where related party loans are non-interest bearing or provided on concessional terms, management has considered whether any material difference exists between the carrying value and fair value. Based on this assessment, no material fair value adjustment has been recognised at 30 June 2025.

For personal use only

10. Events Occurring After the Balance Date

On 5 November 2025, the Managing Director has personally made a facility available to the consolidated entity of \$1 million to assist the consolidated entity in meeting its obligations as and when they fall due for a period of at least 12 months.

On 5 December 2025, the consolidated entity secured an extension to 24 March 2027 on the repayment of its syndicate loan as disclosed in Note 5 Borrowings. As at 31 October 2025, the amount of the secured loan has reduced to \$2,332,939.

On 5 December 2025, a letter of support was received from the directors to defer settlement of \$808,000 in liabilities payable to the Directors until such time that the consolidated entity can make these payments without impacting its solvency.

Apart from the above, there were no other matters or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect:

- a. The Group's operations in future financial years; or
- b. The results of those operations in future financial years; or
- c. The Group's state of affairs in future financial years.

11. Restatement of comparatives

Correction of error

An error was identified in relation to the classification of assets as at 31 December 2024, wherein assets which were actively marketed for sale were incorrectly classified as property, plant and equipment. This error resulted in property, plant and equipment being overstated by \$6,700,000 and assets held for sale being understated by \$6,700,000.

The consolidated entity has rectified this error in the financial half-year ending 30 June 2025, resulting in retrospective restatement of the financial year ending 31 December 2024.

Extracts (being only those line items affected) due to correction of this error are disclosed below:

Statement of financial position at the end of the earliest comparative period

	31 December 2024		31 December 2024
	\$	\$	\$
	Reported	Adjustment	Restated
Assets			
Current Asset			
Assets Held for Sale	-	6,700,000	6,700,000
Total Current Assets	3,689,305	6,700,000	10,389,305
Non-Current Assets			
Property, plant and equipment	6,700,000	(6,700,000)	-
Total Non-Current Assets	6,766,000	(6,700,000)	66,000
Total Assets	10,455,305	-	10,455,305

The correction of the error has not resulted in changes in the measurement of the asset reclassified and therefore neither impacted the profit or loss, nor the opening accumulated losses.

12. Contingent liabilities

At 30 June 2025, the Group had no contingent liabilities (31 December 2024: nil).

The Directors are not aware of any contingent liabilities or contingent assets that may materially affect the Group's financial position or performance subsequent to the reporting date.

Epsilon Healthcare
30 June 2025

Directors' Declaration

In the Directors' opinion:

- (a) the financial statements and notes set out on pages 7 to 19 are in accordance with the *Corporations Act 2001*, including:
 - (i) giving a true and fair view of the financial position of the Group as at 30 June 2025 and of its performance, as represented by the results of its operations and its cash flows, for the half year ended on that date;
 - (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*, Corporate Regulations 2001, and other mandatory professional reporting requirements
- (b) there are reasonable grounds to believe that Epsilon Healthcare Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors made pursuant to section 303(5)(a) of the *Corporations Act 2001*.



Alan Beasley

Chairman

16 December 2025

Sydney, Australia

RSM Australia Partners

Level 27, 120 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007

T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199

www.rsm.com.au

INDEPENDENT AUDITOR'S REVIEW REPORT To the Members of Epsilon Healthcare Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the accompanying half-year financial report of Epsilon Healthcare Limited ('the Company') and its controlled entities (together referred to as 'the Group') which comprises the consolidated statement of financial position as at 30 June 2025, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, and notes to the financial statements, including material accounting policy information and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Epsilon Healthcare Limited is not in accordance with the *Corporations Act 2001* including:

- a) giving a true and fair view of the Group's financial position as at 30 June 2025 and of its performance for the half-year ended on that date; and
- b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and Corporations Regulations 2001.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Epsilon Healthcare Limited, would be in the same terms if given to the directors as at the time of this auditor's report.

Directors' Responsibility for the Half-Year Financial Report

The directors of Epsilon Healthcare Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the Group's financial position as at 30 June 2025 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A blue ink signature, likely belonging to a representative of RSM Australia Partners.

RSM AUSTRALIA PARTNERS

A blue ink signature, likely belonging to B Y Chan.

B Y CHAN
Partner

Dated: 16 December 2025
Melbourne, Victoria